PharmiWeb9h
IMFINZI® (durvalumab) approved in the US as first…
AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
PharmiWeb14h
Imfinzi approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
Junshi Biosciences Announces Toripalimab’s Approval in Singapore
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
Frontiers28d
The relationship between systemic therapies and low skeletal muscle mass in patients with intermediate and advanced hepatocellular carcinoma
National Health Commission Guidelines for the Diagnosis and Treatment of Primary Hepatocellular Carcinoma, and National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN ...
ascopubs.org29d
Management of Advanced Hepatocellular Carcinoma: A Review and Practical Guide
Undisclosed Conflicts of Interest in Japanese Cancer Clinical Trials: A Cross-Sectional Study of Author-Pharmaceutical Industry Financial Relationships Global incidence of hepatocellular carcinoma ...